StockNews.AI
UTHR
StockNews.AI
111 days

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

1. United Therapeutics records 17% revenue growth to $794.4 million in Q1 2025.

Earnings
-0.64%Current Return
VS
+1.15%S&P 500
$300.7604/30 06:35 AM EDTEvent Start
$298.8505/01 01:41 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

The 17% revenue growth exceeds market expectations and aligns with strong historical performance. Previous revenue growth trends have positively influenced UTHR's stock performance.

How important is it?

The strong financial results indicate solid operational performance, likely boosting investor confidence in UTHR.

Why Short Term?

Immediate investor reaction to earnings can impact stock prices quickly, as seen in past earnings reports.

Related Companies

VRTXAMGNREGN
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said Martine Rothblatt, Ph.D., Chair.

Related News